May 2019 Issue Table Of Contents

From The Editor

• Thank Goodness Biopharma Doesn’t Fear Failure

Feature Articles

• Alkermes And Richard Pops — The Evolution Of A Company And Its Leader
• GlycoMimetics Aiming At Tough Targets
• Medicines360 On A Mission For Women

Capitol Perspectives

• Rebate Rule Pends As Congress Begins Moving Rx Bills

CEO Corner

• From Academia To Pharma CEO: Challenges And Lessons Learned

From Principles and Policy to Execution

• What Drives Better Public Health Policies And Superior Patient Outcomes

Companies To Watch

• Provention Bio

Industry Research

• How Prevalent Are PPAs In Phase 2/3 Research?

Inside The Industry

• Comorbidities, Multiple Drugs, And Kidney Transplant – What To Do?
• Why Data Is Fundamental To Drug Repurposing For Common Conditions
• Maximizing Patent Term On Drug Patents By Avoiding Applicant Delays
• How AI Can Accelerate Life Sciences
• Life Sciences Industry On Uptick In Virginia
• The Impact Of A Biotech CEO On Company Growth
• The Main Obstacles To A Pharma 4.0 Program And How To Deal With Them

Industry Leader

• A Different Path To An IPO
• Greater Rigor Is Needed To Enable Real-World Evidence To Reach Its Full Potential
• Data Analytics Are Unlocking Valuable Cold-Chain Insights

Leadership Lessons

• How To Successfully Leap Toward A New Form Of Knowledge

Ask The Board

• As Governments Develop Policies And Regulatory Guidelines Around AI, What Advice Do You Have For Pharma Leaders On AI Implementation?
• How Do You View The Emerging Field Of Anti-Aging Therapies?  Is This Therapeutic Approach Ready Now, Five Years Away, Or A Pipe Dream?
• What Role Should The Pain Therapeutics Industry Play In Combatting The Opioid Epidemic?